Advanced Search
DING Jinxi, LIU Weijing, LI Wei, LIU Yangyang, BAI Gengliang. Analysis of orphan drug accessibility and marketing authorization system in China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 111-117. DOI: 10.11665/j.issn.1000-5048.20140121
Citation: DING Jinxi, LIU Weijing, LI Wei, LIU Yangyang, BAI Gengliang. Analysis of orphan drug accessibility and marketing authorization system in China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 111-117. DOI: 10.11665/j.issn.1000-5048.20140121

Analysis of orphan drug accessibility and marketing authorization system in China

  • According to the status-quo of orphan drug access in China, this paper constructedan index evaluation system so as to provide referable foundationfor establishing and improving orphan drug authorization system. Study results indicated that the less-improved orphan drug marketing authorization system, poorer orphan drug availability, supply capacity and affordability compared with developed countries and regions severely affected patients′ timely medication and hindered orphan drug industry development. With reference to foreign countries, it is urgent to improve orphan drugs marketing authorization system for the purpose of encouraging orphan drug R&D and improving the health benefits of patients.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return